Pharmaron at ASGCT 2025: Advancing the Future of Cell and Gene Therapy
Capabilities
Supporting Global Innovation in Translational Research
The 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT 2025), held in New Orleans from May 13 to 17, 2025, gathered leading scientists, clinicians, and biopharmaceutical partners to advance the frontiers of cell and gene therapy. The event brought together a global community of experts to share the latest scientific advances, explore new technologies, and strengthen collaborations across the field. Pharmaron’s team was on-site to highlight our comprehensive services—from process development and GMP manufacturing to analytical testing and regulatory support.
A Hub for Scientific Collaboration and Therapeutic Innovation
At ASGCT 2025, Pharmaron reinforced its role as a strategic partner across the therapeutic lifecycle—from preclinical discovery to regulatory submission and commercial production.
Gerald Craig, Director of Business Development, emphasized the event’s value:
“Attending ASGCT is essential for staying at the forefront of innovation in cell and gene therapy. It’s where pioneering science is unveiled, long-standing relationships are rekindled, and transformative new partnerships take shape. As a key partner from discovery through commercialization, Pharmaron is proud to support this vibrant ecosystem—continuously evolving to enable new modalities, empower global partners, and accelerate the advancement of breakthrough therapies for patients worldwide.”
Pharmaron’s participation included technical presentations, poster sessions, and one-on-one discussions that explored:
- AAV process optimization strategies
- CMC development for gene-based products
- In vitro cytotoxicity and potency testing assays
Each presentation illustrated the integration of scientific rigor with translational applicability, resonating with both academic and industry stakeholders.
Scientific Highlights: Poster Presentations at ASGCT 2025
Pharmaron presented five scientific posters covering critical development topics. One standout was a dual AAV potency assay co-developed with iECURE. This work showcased a validated, functional in vitro method to assess transgene expression and activity—a foundational requirement for clinical translation. All posters can be downloaded below.
One of Pharmaron’s posters, created in collaboration with iECURE, is outlined here by presenter Vibhor Gupta:
“Our poster on the in vitro potency assay for dual AAV product, developed in collaboration with our sponsor iECURE, highlighted a robust method to evaluate transgene expression and functional activity. The audience responded positively, appreciating the scientific rigor, clarity of results, and its translational relevance to gene therapy development. The engaging discussions and insightful questions reflected strong interest and validation from both academic and industry peers.”
Cell-Based Potency Assay for ECUR-506
These contributions underscore Pharmaron’s leadership in analytical development and commitment to accelerating therapy readiness through innovation and compliance.
Cell and Gene Therapy Development: Pharmaron’s End-to-End Support
With facilities and experts spanning process development, GMP manufacturing, analytical testing, and regulatory guidance, Pharmaron delivers tailored solutions that align with program needs at every stage. The company’s integrated services are purpose-built to overcome technical bottlenecks, de-risk development, and streamline time-to-clinic.
- Flexible engagement models that scale from discovery to commercialization
- Expertise in AAV, LV, mRNA, and other gene therapy platforms
- Regulatory-aligned assay validation and GMP-compliant production pipelines
Targeted CMC Development for Gene Therapy
HTPD and DOE Strategies for AAV Manufacturing
In Vitro Cytotoxicity Assays for CAR-T Cell Therapy
AAV Characterization via Metabolomics Analysis
